Orion Oyj is a Finland-based pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals along with active pharmaceutical ingredients. Operating primarily in F... Orion Oyj is a Finland-based pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals along with active pharmaceutical ingredients. Operating primarily in Finland, Scandinavia, Europe, North America, and internationally, it serves specialists, general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company structures its business into Proprietary Products, featuring patented prescription medicines in key therapy areas such as central nervous system disorders like Parkinson's disease (Entacapone, Stalevo), oncology (Nubeqa for prostate cancer, Fareston for breast cancer), critical care (Simdax for heart failure), and respiratory conditions via Easyhaler pulmonary drugs. Its Specialty Products division offers generic prescription drugs, self-care items, and veterinary medicines for pets and production animals, including Domosedan and Antisedan. Founded in 1917 and headquartered in Espoo, Orion Oyj demonstrates strong financial health with high returns on capital and equity, a robust gross margin around 60%, and steady revenue growth, positioning it as a significant player in the global healthcare sector.
Energy Management data not yet covered for Orion Oyj
We have not yet reviewed Orion Oyj's disclosures for Energy Management data.
If this data is relevant to your work, you can submit a data coverage request and our team
will investigate the company's disclosures and capture the data if available.